# Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

> **NCT01358864** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 678 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** BI 201335
- **DRUG:** Pegylated Interferon-alpha (IFN)
- **DRUG:** Ribavirin (RBV)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01358864
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-02
- **Final completion:** 2014-05
- **Target enrollment:** 678 (ACTUAL)
- **Last updated:** 2016-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358864, "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01358864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*